Thursday, 29 March 2018

Gene Delivery System Market is Envisaged to Hit US$ 4,281.0 Mn by 2025


Transparency Market Research (TMR) has published a new report titled “Gene Delivery System Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. According to the report, the global gene delivery system market was valued at approximately US$ 2,227.8 Mn in 2016 is projected to expand at a CAGR of over 7.8% from 2017 to 2025, The report suggests that increasing in incidence of chronic diseases, rise in technological advancement in administration of drug delivery are projected to boost the market from 2017 to 2025. Key players introduce advanced technologies for drug delivery systems in North America and Europe; therefore, these regions are likely to account for a dominant share of the global gene delivery system market. Changing lifestyle and increase in incidence of chronic diseases in emerging markets such as China and India are likely to boost the market in Asia Pacific. The market in the region is expected to expand at a CAGR of around 8.6% from 2017 to 2025.


High Cost of Gene Delivery Systems is a Key Inhibitor for the Global Gene Delivery System Market

The cost of gene delivery system is significantly high, hence it is not affordable to all income groups. Additionally, lack of reimbursement in developing and under developed countries is likely to restrain the market. For instance, the cost of Spinraza, marketed by Biogen and used for the treatment of spinal muscular atrophy, is around US$ 750,000 per patient in the first year and US$ 375,000 annually thereafter. The cost of Cinryze, marketed by Viropharma used for the treatment of hereditary angioedema, is more than US$ 417,000 per patient per year. Moreover, rise in incidence of rare diseases increases the demand for treatment options. This, in turn, increases the cost of treatment due to less availability. Gene delivery targets only the affected region. Hence, stringent regulations lead to drug recalls. Therefore, gene delivery drugs are not sold over-the-counter.

Combined Hybrid Delivery System Segment to Lose Market Share

The report offers detailed segmentation of the global gene delivery system market based on delivery system, application, and route of administration. The delivery system is segmented into viral gene delivery system, non-viral gene delivery system, and combined hybrid delivery system. The combined hybrid delivery system segment is expected to lose market share during the forecast period primarily due to increase in demand for viral gene delivery system. Rise in incidence of genetic disorders with a different pattern of inheritance increases demand for gene delivery systems worldwide. Increase in application of viral gene delivery for the treatment of several chronic diseases such as cancer fuels the segment. The non-viral gene delivery system segment is likely to maintain market share during the forecast period. Several advantages of non-viral vectors over viral vectors such as lack of immunogenicity, low toxicity, and potential for tissue specificity drive the segment.


Urology Segment to Expand at Considerable Pace during the Forecast Period

Based on application, the oncology segment dominates the global gene delivery system. Increase in incidence of cancer worldwide, drives the segment. According to WHO report (2017), around 1 in 6 deaths occurs due to cancer globally. The urology segment accounted for market share of 7.0% in 2016. The segment is a projected to expand at a considerable pace due to increase in number of chronic kidney diseases and rise in incidences of kidney and liver cancer. According to World Kidney Day a global awareness campaign, 8% to 10% of adults have some form of kidney disorder globally.

Inhalation Segment to Lose the Market Share

In terms of route of administration, the injectable segment dominated the market with share of 43.8%. The injectable route of administration is used for rapid drug absorption. Drugs with low oral bioavailability are administered through intramuscular or subcutaneous route. The inhalation accounted for a small share of the market in 2016; however, is expected to lose market share during the forecast period. Drugs used for the treatment of lung diseases such as bronchodilators and steroids are administered through inhalation to achieve rapid action.


Asia Pacific to Register Exponential Growth due to Increase in Incidence of Diseases

The market in Asia Pacific is expected to expand at a CAGR of 8.6% during the forecast period. Asia Pacific constituted 19.8% share of the market in 2016. Increase in incidence of several acute and chronic diseases in Asia Pacific drives the market in the region. India has high incidence of infectious diseases such as tuberculosis. According to WHO report (2015), India had 2.8 million tuberculosis patients, which was nearly 27.3% of global TB incidence, followed by Indonesia (9.8%), and China (8.8%). North America and Europe account for significant share of the global gene delivery system market due to increase in prevalence of cancer in these regions. According to WHO report 2016, 31% of all deaths were caused by cancer and 2% by diabetes in France.


Key Players such as Novartis AG, Amgen Inc., Oxford BioMedia plc, and SIBIONO to Lead the Global Gene Delivery System Market

Leading players operating in the global gene delivery system market include Novartis AG, Amgen Inc., Oxford BioMedia plc., SIBIONO, Shanghai Sunway Biotech Co. Ltd., Pfizer Inc., Bayer AG, Johnson & Johnson Services Inc., Human Stem Cells Institute, and Epeius Biotechnologies Corporation. Strong gene delivery system pipeline to drive the global gene delivery system market.

Posted by at No comments:
Labels:

Ophthalmology Surgical Devices Market is Envisaged to Hit US$ 11.0 Bn by 2025

The global ophthalmology surgical devices market was valued at approximately US$ 7,000.0 Mn in 2016 and is projected to register a compounded annual growth rate (CAGR) of over 4.0% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled “Ophthalmology Surgical Devices Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. The report suggests that technological advancements and presence of leading players is projected to augment the demand for ophthalmology surgical devices in the next few years (from 2017 to 2025). North America dominates the global ophthalmology surgical devices market, due to high preference for surgical procedures for eye treatment in the region. Emerging markets such as China, India, Argentina, and Brazil are likely to promote growth of the market in Asia Pacific and Latin America from 2017 to 2025.

Read Report Overview: https://www.transparencymarketresearch.com/ophthalmology-surgical-devices-market.html

Strategic Collaborations and High Unmet Needs for Refractive Surgeries to drive Global Ophthalmology Surgical Devices Market

Globally, disorders such as cataract, glaucoma, and age-related macular degeneration (AMD) are the leading causes of blindness and visual impairment. The burden of eye diseases across the globe is expected to increase significantly in the next few years. According to a report published by the World Health Organization (WHO) in 2010, cataract was responsible for causing blindness in 20 million people, which represented around 51% of the world blindness. Glaucoma was estimated to cause blindness in 4.5 million people, which was around 12% of the global blindness. The continuing worldwide demographic trend of people developing myopia is expected to augment the demand for refractive surgeries required to treat the disorder in the next few years. The rate of prevalence of myopia is as high as 70% or more in countries in East Asia. Companies in the ophthalmology surgical devices market are increasingly collaborating with one another as well as with research institutes in order to develop new technologies to address the current unmet needs for eye care. In May 2016, Bausch + Lomb and HOYA Surgical Optics entered into an exclusive agreement, which helped the former to market and commercialize the latter’s wide portfolio of injectors and intraocular lenses (IOLs) in the U.S.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=41633

Glaucoma Surgery Devices Segment to expand at a High Rate

The cataract surgery devices segment dominates the global ophthalmology surgical devices market in terms of revenue. Factors such as launch of new and innovative products, large number of patients with cataract, and government initiatives for promotion of cataract surgeries are likely to fuel the segment during the forecast period. The glaucoma surgery devices segment is estimated to expand at a CAGR of more than 4.0% during the forecast period. Factors such as rising adoption of minimally invasive glaucoma surgeries, increasing elderly population, and growing awareness among people are driving the glaucoma surgery devices segment. According to a study published by the American Academy of Ophthalmology, the prevalence of glaucoma in people aged 40–80 years in the U.S. was 64.3 million in 2013 and is set to increase to 76.0 million by 2020 and 111.8 million by 2040.

Hospitals Segment dominates in terms of Market Share

Based on end-user, the market has been classified into hospitals, ambulatory surgical centers, and ophthalmic clinics. The hospitals segment holds a major market share. The segment is estimated to expand at a CAGR of more than 4.0% during the forecast period. High preference for hospitals by patients with cataract and diabetic retinopathy, presence of a large number of hospitals with highly equipped technologies, and favorable health care insurance coverage are key factors driving the hospitals segment. The segment is likely to be followed by the ophthalmic clinics segment in the next few years. Increase in the number of ophthalmologists and independent optometrists is a key fueling factor for the ophthalmic clinics segment.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=41633

Asia Pacific to offer High Incremental Opportunity

In terms of value, North America led the global ophthalmology surgical devices market in 2016. Rapid adoption for newer technologies and large pool of patients with eye diseases are factors responsible for the major share held by North America in the global market. However, various governments in the region are offering funds for R&D, encouraging pioneering research in the field of ophthalmic laser. Europe is the second-largest market for ophthalmology surgical devices. Increasing baby boomer population and rising incidence of eye disorders in the region are likely to propel the Europe ophthalmology surgical devices market during the forecast period. Increased participation of governments in the development of health care infrastructure and increasing disposable income of people in the region fuel the Asia Pacific ophthalmology surgical devices market. The market in Middle East & Africa was valued at approximately US$ 190.0 Mn in 2016 and is likely to expand at a CAGR of more than 3.0% from 2017 to 2025. Latin America and Middle East & Africa are likely to offer immense growth opportunities to the ophthalmology surgical devices market during the forecast period. Large number of cataract surgeries performed in countries such as Argentina and Bolivia, significant improvements, and initiatives by governments in these regions are factors that fuel the ophthalmology surgical devices market in Latin America and Middle East & Africa.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=41633

Key Players such as Alcon, Johnson & Johnson, Vision Care, Inc., and Carl Zeiss Meditec AG to continue to lead Global Ophthalmology Surgical Devices Market

The report also provides profiles of leading players operating in the global ophthalmology surgical devices market such as Alcon, Carl Zeiss Meditec AG, Johnson & Johnson Vision Care, Inc., Bausch & Lomb, Inc., IRIDEX Corporation, Lumenis Ltd., NIDEK CO., LTD., STAAR Surgical Company, HOYA Corporation, and Glaukos Corporation. Launch of new products and strengthening of product distribution channels across different geographies are key strategies adopted by several major players. Carl Zeiss Meditec AG aims to maintain balanced distribution of revenues across individual markets. The company currently generates around 33% of its revenues from the market in EMEA, the Americas, and APAC.

More Trending Reports by Transparency Market Research -

Posted by at No comments:
Labels:

Circular Dichroism Spectrometers Market is Envisaged to Hit US$ 51.0 Mn by 2025

The global circular dichroism (CD) spectrometers market was valued at approximately US$ 28.0 Mn in 2016 and is projected to register a CAGR of more than 6.0% from 2017 to 2025, according to a new report titled, “Circular Dichroism (CD) Spectrometers Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025” published by Transparency Market Research. The report suggests that technical advancement in CD spectroscopy, in terms of new modality, is expected to expand its applications, thereby boosting the demand for the product during the period, 2017 to 2025. As key players introduce their advanced CD spectrometers and new add-on accessories in the developed markets such a North America and Western Europe, these regions are projected to account for a dominating share of the global CD spectrometers market. Surge in public and private sector funding for R&D programs in the emerging markets such as China and India is projected to boost the growth of the CD spectrometers market in Asia Pacific at a CAGR of around 7.0% from 2017 to 2025.


Expanding applications of FDCD and Stopped Flow CD in proteomics study to boost CD spectrometer uptake

CD spectrometers are a type of analytical instrument used to study the molecular structure and chiral activity of biomolecules and other organic compounds. CD spectrometers are widely used in the study of proteins, DNA, and their conjugates. Earlier, CD spectrometers had limited applications which had restricted their adoption to academic institutes only. In recent times, key suppliers and researchers in CD spectrometers have developed new modalities of the product, such as fluorescence detected CD, magnetic CD, vibrational CD, circularly polarized luminescence (CPL), and stopped flow CD, which have supported researchers to perform in-depth study of biomolecule’s molecular structure and chiral activity at their ground state, photon excitation state, and also the impact of various factors such as temperature, pH, salinity, etc. on these attributes. As the pharmaceutical industry and researchers are hiking their R&D expenditure on new therapeutic entities such as biological drugs, demand for CD spectrometers is anticipated to surge up. However, CD spectrometer is an expensive capital equipment, which requires specialized infrastructure and skilled workforce. Moreover, use of alternative analytical tools such as Raman spectroscopy, Nuclear Magnetic Resonance (NMR) spectroscope, and X-ray crystallography is anticipated to restrain the uptake of CD spectrometers.


Multiple Light Source CD Spectrometers to Gain Market Share

The report offers detailed segmentation of the global circular dichroism (CD) spectrometers market based on product and end-user. Among the product types studied, the circularly polarized light sources segment is poised to account for the leading share of the global market during the forecast period from 2017 to 2025. The circularly polarized light sources CD spectrometers segment is expected to get a boost due to high demand for the product in the emerging markets; easy assembly and operation and comparatively low price of these spectrometers are the factors driving their market share. The multiple light sources CD spectrometers segment is anticipated to witness rapid expansion during the forecast period at a CAGR of around 7.0%. These CD spectrometers provide chiral activity’s study of a biomolecule at various wavelengths and in shorter time. The linearly polarized light sources segment is estimated to lose its market share during the forecast period from approximately 16.0% in 2016 to approximately 15.0% by 2025.


Government and Private Research Organizations in Emerging Markets Poised to be Lucrative End-users

Among end-users, government and private research organizations are the leading contributors to the global CD spectrometers market. The segment is projected to constitute the dominant share of the global CD spectrometers market during the forecast period and is estimated to expand at a CAGR of around 7.0% from 2017 to 2025. Upsurge in funding from the public and private sectors for various research programs in developed markets is anticipated to propel this growth. Rising number of government and private institutes and universities in the emerging markets such as China, India, and Southeast Asia is estimated to fuel the market. Contract research organizations (CRO) is projected to be an emerging end-user segment of CD spectrometers in the emerging markets.

Asia Pacific to Resister Exponential Growth and Offer Huge Incremental Opportunity

In terms of value, North America was the leading contributor to the global circular dichroism (CD) spectrometers market in 2016. High public and private sector funding for research programs in the U.S. is one of the contributing factors toward the major share of the CD spectrometers market in the region. Stringent regulations and policies regarding documentation of the chiral nature of drug entities in the U.S. is leading the pharmaceutical industry and CROs to adopt analytical tools such as CD spectrometers. According to the National Center for Science and Engineering Statistics (NCSES), expenditure on R&D in the U.S. increased at a CAGR of 4% from 2013 to 2015. The trend is estimated to continue in the near future. Increasing cost of R&D processes and stringent rules and regulations for R&D in the developed regions such as the U.S. and Western Europe are compelling pharmaceutical companies to outsource their R&D activities to CROs in Asia Pacific. Moreover, initiatives undertaken by governing bodies in the region to develop higher education infrastructure is expected to fuel the CD spectrometers market in Asia Pacific at a CAGR of around 7.5% from 2017 to 2025.


Key Players such as AstraZeneca, Bayer AG and Merck & Co., Inc. are Likely to Continue to Lead the Global Cardiovascular Drugs Market

The report also provides profiles of leading players operating in the global circular dichroism (CD) spectrometers market such as Jasco, Applied Photophysics Ltd., Bio-Logic Science Instruments, Inc., Aviv Biomedical, Inc., On-Line Instrument Systems, Inc. (Olis), and Bruker. Most of these key players emphasize on development of new CD modalities such as fluorescence detected CD, stopped flow CD, vibrational CD, etc. These modalities are offered as an add-on accessory or standard feature of CD spectrometer. Expansion of geographic reach through collaborations and distribution agreements is a key strategy adopted by these key players; for example, Hinds Instruments, a manufacturer of photoelastic modulators, has developed microplate CD reader and licensed it to Bio-Logic Science Instruments, Inc. for global distribution.

More Trending Reports by Transparency Market Research -


Posted by at No comments:
Labels:

Gynecological Devices Market is Envisaged to Hit US$22,589.9 mn by 2023


The global gynecological devices market is marked by a high degree of fragmentation due to the presence of several large and small manufacturers, reports Transparency Market Research (TMR) in a new business intelligence study. This leaves ample room for market consolidation in the near future. Nevertheless, top companies namely Boston Scientific Corporation, Cooper Surgical, and Olympus Corporation hold prominence on account of their extensive product portfolio and geographical outreach. These companies are vying to introduce non-invasive devices to serve a larger consumer base that will also help expand their geographical outreach. With increasing demand for medical help for women-centric health issues, there lies immense scope of growth for players in the gynecological devices market.


At present, small as well as regional players hold significant share in the gynecological devices market. However, increasing entry barriers and stringent regulations for product approval are limiting the entry of new companies. Insufficient funding from venture capitalists is also challenging new companies to enter this market.

As per projections of a TMR report, the global gynecological devices market will clock 4.8% CAGR between 2017 and 2023. This will translate opportunities in the market to generate a revenue of US$22,589.9 mn by 2023 from US$17,015.9 mn in 2017. In terms of device type, gynecological surgical devices hold prominence in the market. Rising prevalence of single incision laparoscopic surgeries and advances in conventional endoscopic surgeries account for advances in gynecological surgical instruments. Geography-wise, North America is a lucrative market for gynecological devices due to the early adoption of advanced gynecological devices.


Efforts of Global Health Organizations for Women Health a Boon for Market

First and foremost, rising incidence of gynecological disorders such as uterine fibroids, cervical cancer, and menorrhagia is driving the gynecological devices market. In developing countries, healthcare infrastructural development and technologically advanced diagnostic services is favoring the gynecological devices market. An increasing awareness among women in these countries regarding therapeutics for gynecological diseases is also stoking demand for gynecological devices. Global health organizations and non-profit organizations conduct periodic health check-ups in developing and underdeveloped countries for women health. This stokes demand for gynecological devices.

In urban areas, modern lifestyle and increasing professional and personal stress are also related to gynecological conditions. This is necessitating routine check-up for women-centric health issues that may require gynecological devices at secondary stage of therapeutics.


Rising Preference for Minimally Invasive Procedures Stokes Demand

At present, acceptance of minimally invasive procedures generally is on the rise. This is because minimally invasive surgeries involve shorter hospital stay and faster recovery. Minimal scarring and ease of post-surgery care are leading individuals to opt for minimally invasive procedures. Gynecological surgery at one time meant big painful incisions, longer recovery periods, and intense monitoring. Due to this, open exposure surgical hysterectomies is increasingly being replaced with minimally invasive hysterectomies that involve the use of an electric morcellator surgical device.
Increasing public and personal healthcare expenditures and rising awareness of therapeutics for gynecological diseases in developing countries is cementing the growth of this market. Women health in these countries is increasingly being considered important for economic development thus drawing the attention of national governments.


However, long hauls for product approval and delays for product approval from regulatory authorities is providing headwinds to the growth of gynecological devices market. Stringent documentation and compliance requirements delay commercial availability of advanced first-mover products.
Posted by at No comments:
Labels:

Advanced Wound Care Management Market Will Likely to Expand at a Steady CAGR of 6.3% by 2024

The worldwide market for advanced wound care management market is a consolidated one with a few companies that are technologically and scientifically advanced, reports Transparency Market Research (TMR) in a new report. The four top companies, namely Molnlycke Health Care, ConvaTec Group plc., Smith and Nephew, and Acelity L.P. Inc. held close to 65% market share in 2015. These topnotch companies are making significant investments in R&D so as to develop innovative products and stay in the lead. Competitive prices offered by top shots renders intense competition amongst them.

As per the TMR report, the global advanced wound care management market is likely to display a CAGR of 6.3% between 2017 and 2024. Expanding at this rate, the market which stood at US$7,268.1 mn will become worth US$11,161.6 mn by the end of 2024. Among the key product types, advanced wound dressings currently hold leading share in the overall market. Going ahead, the segment is likely to expand at the leading growth rate. Venous leg ulcers, on the basis of type of wound, holds the leading market share due to high incidence of leg ulcer cases.

Read Report Overview: https://www.transparencymarketresearch.com/advanced-wound-care-management-market.html

Rising Literacy in Developing Countries Accounting for Early Medical Help for Wounds Benefits Market

The advanced wound care management market is primarily driven by the rising incidence of chronic wounds. Chronic wounds generally require longer healing time and if not treated on time can lead to complications. Chronic wounds account for significant burden on public healthcare systems worldwide that have socioeconomic implications. According to statistics, currently more 4.5 million individuals suffer from pressure ulcers and more than 9.7 million individuals with venous ulcers.
Diabetic ulcers – a type of chronic wounds are growing at a rapid pace due to increasing incidence of Type 1 and Type 2 diabetes especially in developed economies. Diabetic ulcers is growing at 9% annually which outpaces the rate of development of new therapeutics. Patient pool of diabetic ulcer patients is currently close to 10.0 million.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16139

Worldwide, growing elderly population above the age of 65 years is stoking demand for advanced wound care. As per statistics of the U.S. Census Board, individuals above the age of 65 years are estimated to account for 20% of the population by 2030. This population that is susceptible to falls and injuries require longer healing time that can impact quality of life and can also cause social distress. According to the Wound Healing Society, in the U.S., almost 15% individuals above the age of 65 years suffer from chronic wounds, which mainly include venous stasis ulcers, pressure ulcers, and diabetic foot ulcers.

Increasing patient awareness about early treatment of wounds is stoking demand for wound care products. Rising disposable income and increasing literacy especially in developing countries is leading individuals to seek early medical help for wounds before it leads to infection or other complications.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16139

Apart from this, commercial availability of different skin substitutes for treating chronic wounds is benefitting the advanced wound care management market. Skin substitutes help reduce healing time and reduce the risk of complications associated with burns, trauma, surgical cuts, and skin breakouts.

Limited Reimbursement Scenario Challenges Growth in the U.S.

On the downside, high cost of advanced wound care products over traditional wound dressing account for their limited adoption. For instance, in the U.S., the cost of managing pressure ulcer with advanced wound care products ranges from US$7,000 to US$55,000. Such costs are mostly affordable by the affluent thus makes for a smaller market. Limited reimbursement for advanced wound care products is a restrain to the growth of this market in the U.S.
Posted by at No comments:
Labels:

Friday, 23 March 2018

Wound Healing Market is Expanding at a CAGR of 4.8% by 2025

The global Wound Healing market was valued at approximately US$ 23.3 Bn in 2016 is projected to register cumulative annual growth rate (CAGR) of over 4.8% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled “Wound Healing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. The report suggests that increasing patient pool for chronic wounds is likely to spur the demand of wound healing products in the coming years (2017 to 2025). As key players introduce technologically advanced wound healing solutions in developed markets such a North America and Europe, these regions are likely to account for dominating share of the global wound healing market. Established presence & wide distribution networks of major players and growing market penetration of emerging players are likely to boost growth of Asia Pacific wound healing market at a CAGR of around 5.3% from 2017 to 2025.

Read Report Overview: https://www.transparencymarketresearch.com/wound-healing-market.html

High Cost of Advanced Wound Care Products to Restrain Global Market Expansion

According to the Centers of Disease Control (CDC) statistics, an estimated 450,000 – 500,000 patients suffer from burn injuries each year in the U.S. The direct costs of treatment of burn injuries in the U.S., was estimated to be around US$ 10.4 Bn. Wounds impose underappreciated burden on the population across the globe and they account for the majority of injuries related to skin. Rise in the prevalence of diabetes and obesity, and increasing adoption rate for wound care therapy devices in developed and emerging markets are likely to fuel the uptake of wound healing products by 2025. However, high price of newly launched and technologically advanced wound care products restricts their demand. Conventional wound healing products are preferred over technologically advanced costly dressings in the emerging economies, despite their slow healing process. The price sensitive market of developing nations thus restricts the growth of advanced wound management technologies, which in turn has attributed for devaluation of the market, thereby restraining growth of global wound healing market.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40535

Wound Closure Agents to Lose Market Share

The report offers detailed segmentation of global Wound Healing market based on product, wound type, and gender. Among the product types studied, wound closure agents segment is poised to account for leading share of the global market during the forecast period from 2017 to 2025. Topical agents segment which comprises hemostatic agents, antimicrobials, wound cleansers, and others are likely to get boost from their ongoing R&D activities, in turn estimating highest number of new product launches in the near future. The wound closure agents segment is anticipated to lose its market share during the forecast period, and is expected to hold a share of 24.0% by 2025 from 28.1% in 2016. Availability of other advanced wound healing products with reduced risk of infection are factors likely to hamper the market share of this segment.

Chronic Wounds to Be the Most Promising Wound Type to Invest In

Among wound types, chronic wounds segment is projected to hold dominant share of global wound healing market during the forecast period and is likely to expand at CAGR of around 5.0% from 2017 to 2025. From chronic wounds, ulcers sub-segment is expected to lead the global wound healing market in terms of CAGR by 2025. As per the Agency for Healthcare Research & Quality (AHRQ), in U.S. US$ 9.0 Bn to US$ 11.0 Bn are spent on pressure ulcers by health care systems annually. Significant patient population, and availability of favorable reimbursement policies which are driving manufacturers’ focus on business expansion in advanced wound care products are projected to fuel this expansion. Significant economic burden of surgical site infections (SSI), and higher treatment costs associated with it is expected to propel the expansion of chronic wound segment during 2017-2025.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40535

Women are to Capture Relatively Significant Market Share during the Forecast Period

In case of women, especially in low and middle income countries, there is significant gap between reported and actual cases of diabetes and chronic wounds, which is anticipated to improve during forecast period. In terms of gender, women segment held 52.9% of global wound healing market share in terms of revenue. Initiatives such as Wound Awareness Week and other outreach programs are projected to increase the awareness in significant patient population.

Asia Pacific to Register Exponential Growth Rate and Offer Huge Incremental Opportunity

In terms of value, North America was leading contributor in global wound healing market in 2016. As per the data published by ‘Wound Care Awareness Week–2017’, the annual cost (including direct as well as indirect costs) of treatment of all types of wounds incurred to health care systems in the U.S. is US$ 50.0 Bn, while the annual cost of amputations exceeds US$ 8.0 Bn. High prevalence of chronic wound in this region is imposing significant economic burden and is increasing demand for affordable care in the U.S., which in turn is driving the growth of wound healing market in North America. Healthcare spending in emerging markets such as China and India are rising, which is fueling the expansion of Asia Pacific wound healing market. Geographical expansion of international players to this region through distribution and licensing agreements with local distributors in the region are anticipated to propel the growth of Asia Pacific in global wound healing market at CAGR of 5.3% from 2017 to 2025. Regaining economic growth in Latin America countries such as Brazil is augmenting healthcare expenditure through rise in private health insurance, entry of international wound healing products manufacturers & health care providers in this region. It is one of the major factor for the estimated growth of Latin America during 2017-2025.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40535

Key Players such as Acelity L.P., Inc., Smith & Nephew plc, and Mölnlycke Health Care AB are Likely to Continue to Lead the Global Wound Healing Market

The report also provide profiles of leading players operating in global wound healing market include Smith & Nephew plc, Integra LifeSciences Corporation, B. Braun Melsungen AG, Mölnlycke Health Care AB, 3M Healthcare, Ethicon, Inc. (Johnson & Johnson), Hill-Rom Holdings, Inc., Cardinal Health, Acelity L.P., Inc., ConvaTec Inc., BSN medical (Svenska Cellulosa Aktiebolaget SCA), Coloplast Group, Medline Industries, Inc., Organogenesis Inc., and Hollister Incorporated. Expansion of wound healing portfolio by acquiring the wound healing platform of emerging players is a key strategy adopted by many key players.
Posted by at No comments:
Labels:

Sterility Testing Market is Expanding at a CAGR of 7.0 % by 2025

The global sterility testing market was valued at approximately US$ 750.0 Mn in 2016 is projected to register cumulative annual growth rate (CAGR) of over 7.0% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled “Sterility Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. The report suggests that increase in research & development activities is outgrowth the demand of sterility testing in the coming years (2017 to 2025). North America dominating the sterility testing market due to establishment of new biopharmaceutical companies as well as quick adoption of advanced technology. The emerging markets such as China, India and Brazil is likely to boost growth of Asia Pacific and Latin America sterility testing market at a CAGR of more than 7.0% from 2017 to 2025.

Read Report Overview: https://www.transparencymarketresearch.com/sterility-testing.html

Technological Advancement and Strategic partnerships to Drive Global Sterility Testing Market

Technological improvements in devices and reagents available for sterility testing have aided in easing the process and contributed to market growth. This change in sterility requirements is an exciting development for the rapid microbial testing business. Manufacturers operating in the sterility testing market have entered into various strategic mergers & acquisitions and partnerships that enabled them to enhance market position and expand customer base. For instance, bioMérieux and Shimadzu have worked in partnership to develop their linear MALDI-TOF mass spectrometry technology for improved incorporation into the microbiology laboratory workflow. Similarly, BD Diagnostics and Bruker entered into a partnership to improve Bruker MALDI Biotyper for microbial identification and antimicrobial susceptibility testing.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=23714

Instruments and Biopharmaceutical Manufacturing Segment Market to Grow At High Rate

The kits and reagent segment dominate the sterility testing market in terms of revenue. The advantages of kits and reagents segment includes product affordability, easy product availability, increase in research and development activities and high awareness for kits and reagents are likely to fuel the growth of the segment. The instruments segment is the highly growing segment at a CAGR of more than 8.0%. Factors such as technological advancement, growing demand for automated products, favorable reimbursement scenario and rapid process are key factors driving the instruments segment. According to the European Federation of Pharmaceutical Industries & Associations, in 2016, the pharmaceutical sector in Brazil and China expanded at a growth rate of 10.0% and 6.9% respectively. The same year, the pharmaceutical sector in the European Union and the U.S. expanded at an average growth rate of 4.5% and 6.3% respectively. In terms of application sterility testing is highly preferred in biopharmaceutical manufacturing. Rising demand for high-quality and innovative products and growing prevalence of chronic diseases are key driving factors for the biopharmaceutical manufacturing segment.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=23714

Traditional Sterility Tests Dominates In Term of Market Share

Sterility tests type is classified into traditional sterility tests and rapid sterility tests. In terms of test type traditional sterility tests contributes high market share. High acceptance among sterility testing service providers, high awareness about traditional sterility tests, low startup cost, high preference for membrane filtration tests are the key factors driving the traditional sterility tests segment. Rapid sterility tests is the highly growing segment at a CAGR of more than 8.0%. Increase in health care investment, technological advancements and rise in investment for research & development are expected to fuel the growth of the rapid sterility tests segment.

Asia Pacific to Offer Huge Incremental Opportunity

In terms of value, North America was leading contributor in global sterility testing market in 2016. Technological advancements, rapid adoption for newer technologies, and presence of a large number of providers of pharmaceuticals as well as medical devices are contributing factor for major share of the North America market. However launch of new, innovative products and an expanding skill base in North America implies that more people in the region will have access to advanced technology during the forecast period. Europe is the second largest market. Rise in research & development activities, increase in export of manufactured products to other countries are likely to accelerate Europe sterility testing market. The increase in number of pharmaceutical and biopharmaceutical companies and rising demand for drug products fueling the Asia Pacific sterility testing market. The Middle East & Africa region was valued at approximately US$ 27.1 Mn and likely to propel at a CAGR more than 6.5% from 2017 to 2025. Latin America and Middle East & Africa will create good market opportunity for sterility testing market. The increasing coverage of private health insurance coverage, rapid population growth, rise in prevalence of lifestyle diseases such as diabetes and cardiovascular disorders etc. are the factors fuel the rest of the Rest of the world sterility testing market.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=23714

Key Players such as Merck KGaA, bioMérieux, Inc and Thermo Fisher Scientific Inc., are Likely to Continue to Lead the Global Sterility Testing Market

The report also provide profiles of leading players operating in global sterility testing market include Merck KGaA, bioMérieux, Inc, Sartorius AG, Thermo Fisher Scientific Inc., Charles River Laboratories International, Inc., Solvias AG, Becton, Dickinson and Company, Rapid Micro Biosystems, Inc. Merger & acquisition activities, new product innovation are the the key strategy adopted by many key players. In July 2015, Celsis International, Ltd., a leading provider of rapid testing systems for bacterial contamination acquired by Charles River Laboratories International, Inc.
Posted by at No comments:
Labels:

Flow Cytometry Market is Expanding at a CAGR of 11.0% by 2025

The global flow cytometry market was valued over US$ 3,072 Mn in 2016 and is projected to register cumulative annual growth rate (CAGR) of over 11.0% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled “Global Flow Cytometry Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. The report suggests that rising demand for advanced medicine due increased chronic and acute diseases globally increasing the pharmaceutical researches and drug discovery operations is spurring the growth of flow cytometry in coming years (2017 to 2025).

Read Report Overview: https://www.transparencymarketresearch.com/flow-cytometry-market.html

The North America and Europe are projected to dominate the global flow cytometry market in the coming years owing to increase in manufacturer focus for business expansion in these regions. Players are continuously developing advanced flow cytometry instruments & products and entering into distribution agreements to fortify their footprints in the North American and European markets. Growing adoption of technologically advanced products manufactured by local manufacturers like Flowcytometry Solutions Pvt. Ltd. is likely to drive the Asia Pacific flow cytometry market. The Asia Pacific flow cytometry market is expected to witness CAGR of over 13% from 2017 to 2025

Flow Cytometry Instruments Dominates the Market Followed by Reagents & Consumables

The report offers detailed segmentation of global flow cytometry market based on technology, product & services, application, and end-user. Among the product & services segment, flow cytometry instrument segment is poised to account for leading share of the global market during the forecast period from 2017 to 2025. Factors attributed to the higher share of the reagent segment in the global market include increased the use of advance flow cytometry instruments in novel drug discovery, and targeted based drug discovery. Reagents & consumables segment is likely to register comparatively higher growth rate in terms of value in the global flow cytometry market during the forecast period owing to continuous innovations in the product technologies by major market players.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40472

Pharmaceutical & Drug Discovery and Diagnostics: Top Two Application Areas of Flow Cytometry

Among applications, Pharmaceutical & Drug Discovery segment is projected to hold dominant share of global flow cytometry market during the forecast period and is likely to expand at CAGR more than 10% from 2017 to 2025. Major factors responsible for the dominance of this segment are continuous innovations in flow cytometry instruments and wide product portfolio of major as well as local manufacturers. For instance In October 2017 Sysmex America Inc. introduced CyFlow Antibodies for the application in clinical flow cytometry. Such continuous new product launches, along with exponentially rising patient base in developed as well as developing countries are likely to drive the segment between 2017 and 2025. According to JAMA oncology, in the year 2015 around 17.5 million new cancer cases was estimated globally, around 8.8 million death observed from cancer, which is nearly 1 in 6 deaths. Software and services segment, accounted for more than 28.0% share of global flow cytometry market in 2016, in terms of value.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40472

Growth of the Asia Pacific Flow Cytometry Market Likely To Be Hinged At China, Japan

In terms of value, North America was leading contributor in global flow cytometry market in 2016. Increased demand of flow cytometry products and increasing prevalence rate of immunological diseases such as HIV/AIDS among the population is the U.S. are some factors contributing for major share of the North America market. However, competition from image analyzer, scanning cytometers, dearth of skilled technician for data interpretation & technical implications are likely to hamper this market. Healthcare spending in emerging markets such as China and India are rising, which is fuelling the expansion of Asia Pacific flow cytometry market. Regaining economic growth in Latin American markets such as Brazil is augmenting healthcare expenditure through rise in private health insurance, entry of international drug manufacturers and health care providers in this region. This factor is likely to propel Latin America flow cytometry market at CAGR of 9% from 2017 to 2025.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40472

Highly Consolidated Market with Top Three Players Accounting For More Than 50.0% of the Global Market

The report also provide profiles of leading players operating in global flow cytometry market Becton, Dickinson and Company (BD), Merck & Co., Inc., and Beckman Coulter, Inc. (Danaher) are major players operating in the market, offering wide range of products such as Becton, Dickinson and Company (BD) offers almost all the flow cytometry products includes instruments, software, antibodies, etc. Merck & Co., Inc. offers flow cytometry instruments, reagents kits, assay kits etc., while Beckman Coulter, Inc. (Danaher) offers advanced technological product as flow cytometry analyzer which offers infrared lasers and ultraviolet with avalanche photodiode sensors. Flowcytometry Solutions Pvt. Ltd. and Sysmex Partec GmbH are the other major players in the developed and developing countries, respectively. Expansion of flow cytometry product portfolio through partnerships to improve drug and biological product analysis is a growing trend in global flow cytometry market. For instance, on 17th January, 2018 Premas Life Sciences Pvt., Ltd. and IncellDx, Inc., signed agreement for diagnosis of solid tumor carcinoma that can now possible to analyzed for protein and molecular biomarkers by flow cytometry. Other prominent players in the global chemiluminescence immunoassay (CLIA) analyzers market include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Bio-Techne., Alere, Inc. and Miltenyi Biotec GmbH.
Posted by at No comments:
Labels:

Thursday, 22 March 2018

Glaucoma Therapeutics Market to Expand at a Modest CAGR of 3.4% by 2024

The global glaucoma therapeutics market is immensely consolidated and the top five players accounted for just under 85.0% of the market in 2015. Among Novartis AG, Allergan plc., Pfizer Inc., Merck & Co., and Santen Pharmaceuticals, Novartis is the clear leader with a massive share of over 33.0%.

Transparency Market Research has observed that most companies have a hold over the market owing to their well-established brands and a strong pipeline of drugs for the treatment of glaucoma. However, loss in the market share of leading companies due to patent expiry is likely to offset the competitive landscape in the coming years.

Read Report Overview: https://www.transparencymarketresearch.com/glaucoma-therapeutics-market.html

The global glaucoma therapeutics market is projected to rise from a value of US$5.7 bn in 2015 to US$7.6 bn by 2024 at a modest CAGR of 3.4% therein.

North America Dominates Global Market by Revenue

Based on drug class, the glaucoma therapeutics market is led by the combination segment, which is projected to account for a share of 25.8% by 2024. Expanding at an 8.8% CAGR from 2016 to 2024, the segment is fueled by the cost-effective nature of these drugs as compared to individual drugs. On the basis of end use, hospitals formed the leading segment of the glaucoma therapeutics market in 2015. The maximum opportunity was also presented by this segment. Hospitals provide healthcare services at an affordable cost to citizens across the U.S., Canada, the U.K., and several other countries in Europe. This has ensured the dominance of the hospitals segment.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16406

Geographically, North America is expected to account for a large share in the glaucoma therapeutics market in terms of revenue owing to the rising usage of highly priced prostaglandins. The region accounted for almost half the market in 2015. Exhibiting a 4.2% CAGR from 2016 to 2024, Asia Pacific presents immense scope for growth. India holds a major share in the APAC market in terms of revenue owing to the rising prevalence of glaucoma in the country and a comparatively lower cost of treatment.

Improving Socio-economic Living Conditions Key in Driving Uptake of Glaucoma Therapeutics
The growing need to offer improved eye care and preserve the vision of the patients among healthcare providers has resulted in the development of enhanced therapeutic options for the treatment of glaucoma. “Although eye drops have, until recent years, been the primary method of treatment, the market has been witnessing an evident shift toward combination drugs,” the author notes. The strong pipeline of combination drugs for the treatment of glaucoma therefore ensures steady growth of this market. Aerie Pharmaceuticals’ pipeline of combination drugs such as Rho Kinase Inhibitor (ROCKi) and norepinephrine transport inhibitor (NETi) is a key example of this development.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16406

In addition to this, an improvement in the socio-economic conditions of people in developing countries has increased spending capacity, which has not only resulted in a rise in healthcare expenditure but also led a surge in awareness about living a healthy lifestyle. This has, in turn, upped the early detection of glaucoma and spurred the demand for glaucoma therapeutics.
In contrast, the possible side effects of glaucoma drugs and the growth of the generic drugs market are likely to be the key deterrents in the coming years.
Posted by at No comments:
Labels:

Tissue Banking Market Opportunity will Rise to US$2.1 billion by 2024

The global tissue banking market features an intensely competitive landscape with the marked presence of a copious number of big original equipment manufacturers and the presence of relatively small number of dedicated facilities that offer services related to tissue banking, finds Transparency Market Research (TMR). The top players operating in the market include Backman Coulter Inc., Panasonic Biomedical, Taylor-Wharton, Brooks Automation, and Thermo Fisher Scientific. Leading companies are focusing on strategic mergers and acquisitions and substantially investing in expanding their product pipelines to attractive regional markets. Several players are also developing technologically advanced equipment for tissue banking activities to gain a competitive edge over others.

Read Report Overview: https://www.transparencymarketresearch.com/tissue-banking-market.html

As the global tissue banking market requires substantially heavy investments to set facilities and the employment of markedly high technical expertise, the landscape is likely to witness surge in competition, observes TMR. The threat of entry from small vendors is, therefore, low. The market is characterized by the strict tissue transplant acts and regulations, which further dissuades the entry of small players.

The global tissue banking market is estimated to reach a valuation of US$2.1 billion by the end of 2024. The market is projected to expand at a CAGR of 11.3% during 2016–2024.
The various equipment type used for tissue banking activity are freezers, storage system, labelling and coding equipment, alarming and coding equipment, and thawing equipment. Of these, the freezers segment accounted for a substantial share in the market in 2015 and is projected to rise at a prominence pace through the forecast timeline. The growth of this segment in fueled by an extensive demand for increasing demand for tissue banking in organ transplant, blood transfusions, cellular therapies, vaccines, and regenerative medicines. This is attributed to its suitability for long-term storage of tissues over an extended range of -18°C to -86°C.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14681

Regionally, Asia Pacific is set to be the most attractive market and is anticipated to rise at a phenomenal pace during the forecast period. The regional market is driven by a large patient population and rapid improvements made in the healthcare infrastructure in recent years.

Extensive Demand for Regenerative Medicines among Aging Population to Boost Market

The drive for the tissue banking market stems from the pressing need for adequate amounts of tissues, primarily for clinical use and research. The growing demand is attributed to the need for harvesting and using transplantable human tissues for replacing and repairing lost or damaged tissues lost on account of aging, physical damage, congenital defects, or diseases. The widening prevalence of cardiovascular diseases (CVD) and neurological disorders, various cancer types, and diabetes in several developing and developed countries is stoking the demand for safe tissue processing, storage, and transportation.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14681

The rapidly aging baby boomer generation in a number of developed nations is expected to bolster the demand for tissue banking activities. A rise in geriatric population in several developed nations is also expected to accentuate the growth of the overall tissue market. The extensive use of bio-banking of normal and tumor cells and stem cells from bone marrow is also accentuating the growth of the market.

The growing popularity of regenerative medicines in hospitals, research and academics institutes, and diagnostic laboratories is a notable factor boosting the tissue market. The rising discretionary spending on healthcare, combined with favorable insurance and reimbursement policies, is a notable aspect accentuating the growth of the market.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=14681

Stringent Set Protocols key Challenge, Research Institutions to Witness Vast Uptake of Transplantable Tissues

The harvesting, processing, and storage of human tissues is riddled with marked complexity and any lapse, even minor, may affect the life of recipients. The copious amounts of funds required for setting a dedicated tissue banking facility is another crucial factor likely to impede the growth of the market to an extent. The need stringent adherence to set protocols for tissue banking activities is a crucial factor likely to cripple the growth of the market.

Be that as it may, recent advances made in regenerative medicines in several developed nations and the rising demand for tissue transplantation for the treatment of chronic diseases and cancer are notable factors expected to accentuate the growth of the market. The market is also expected to benefit from advancements in cryogenic storage technologies. The vastly growing demand for a variety of transplantable tissues in research centers is also expected to provide a robust fillip to the market’s growth.
Posted by at No comments:
Labels:

Advanced Wound Care Management Market to Surge at a CAGR of 6.30% by 2024

The world market for advanced wound care management market is characterized with a marked consolidated vendor landscape due to the market being a technologically intensive one. The demand for significant amount of research and development (R&D) funds has delayed the entry of many of the many small vendors. Emerging market participants are emphasizing on the strategy of competitive pricing so as to fortify their foothold in the world market for advanced wound care management.

The four leading market players, namely Molnlycke Health Care, Smith and Nephew plc, ConvaTec Group plc., and Acelity L.P. Inc. accounted for approximately around 65.0% of the world market in the year 2015, discovers Transparency Market Research (TMR). These topnotch vendors of the said market are continuously making investment in R&D activities and also emphasizing on the development of innovative products so as to stay ahead of the rest of the pack.

Read Report Overview: https://www.transparencymarketresearch.com/advanced-wound-care-management-market.html

The world market for advanced wound care management was valued at around US$ 6,457.0 million in the year 2015. The said market is estimated to expand at a sound CAGR of 6.30% over the period of forecast that extends from 2016 to 2024. With the market progressing at this pace, the said market is predicted to reach a market valuation of around US$ 11,161.6 million by the end of the said forecast period.

North America to Lead the Market with Advanced Treatment Facilities

The major geographical categories of the international market for advanced wound care management are Latin America, North America, the Middle East and Africa, Europe, and Asia Pacific. So far as geographical segmentations are considered, the region of North America held a dominant share of the international market for wound care management in the 2015 and the said region is projected to continue with its regional supremacy over the forthcoming years as well. The growth of the said regional market is attributed with the relentless launch of advanced wound care diagnostics for the purpose of identification of pathogens and coming up of new product lines by the prominent market players. In the meanwhile, the region of Europe is estimated to rise at a substantial pace over the period of forecast. The said regional market is expected to be driven by a burgeoning pool of patient population who are affected with diabetes and vascular disease.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16139

Illness due to Various Lifestyle Factors to Encourage Market Growth

The rising incidences of illness that are caused due to various lifestyle related factors across the world are contributing towards the growth of the said market. Various types of chronic wound like venous leg ulcers, diabetic foot ulcer, and decubitus ulcers are a few of the growth promoting factors for the international market for advanced wound care management.

The increasing instances of mortality due to venous leg ulcers and diabetic foot ulcers amongst the elderly populations is further bolstering the demand for strategies related to advanced wound management in various developed and developing countries. The rising morbidity due to chronic wounds across the global patient populations together with economic repercussions have led to growth of the said market in lesser developed societies and communities. In many of the developed and developing nations, the soaring number of cases of maturity-onset and type I diabetes has resulted in the rising prevalence of diabetic ulcers, thereby accelerating the growth of the said market.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16139
Posted by at No comments:
Labels:

Interventional Radiology Market Opportunity will Rise to US$22.9 bn by 2024

The global interventional radiology market is prognosticated to witness a highly positive growth trajectory in the years to come. According to a report by Transparency Market Research (TMR), the market constitutes to a great extent a merged aggressive scene, with the best five players representing a significant portion of the market in 2015. Philips Healthcare, Hitachi Medical Corporation, GE Healthcare, Toshiba Medical Systems Corporation, and Siemens Healthcare lead the worldwide market attributable to differentiated product profiles, market vicinity, and securing procedures. Product improvement capacities have additionally worked in the support of these organizations throughout the years. With dispatch of innovational products, such as the interventional x-beam hardware assortments EchoNavigator, Allura 3D, and FlexVision, these organizations are relied upon to hold their dominant market position in the following years.

Read Report Overview: https://www.transparencymarketresearch.com/interventional-radiology-market.html

TMR notes that the worldwide interventional radiology advertise was valued to be at US$13.8 bn in 2015 and is anticipated to exhibit a 5.8 % CAGR between 2016 and 2024. On the off chance that the forecast remains constant, the market is relied upon to achieve US$22.9 bn by 2024. Of the key utilizations of interventional radiology, the embolization segment commands about 24% of the market's general valuation in 2015. North America is the regionally dominant market, with almost 38% of the worldwide market share held in 2015.

Demand of Minimally Invasive Procedures to Propel Embolization Segment

Based on technique, the worldwide interventional radiology market is classified into kyphoplasty, expand angioplasty, RF removal, biopsy, embolization, vertebroplasty and angiography. The segment of embolization held a huge share in the market and is relied upon to develop over the coming years on account of riding instances of trauma and injuries over the globe. The popularity for minimal invasive and rising worldwide pervasiveness of strokes will supplement the development of the angiography fragment over the forecast duration.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1337

North America held the regionally dominant position in the worldwide interventional radiology market. This district is predicted to demonstrate a noteworthy ascent notwithstanding the developing interest for minimally invasive procedures and an unending supply of innovative propelled hardware and gadgets. Moreover, rising event of an assortment of diseases, change in innovation, and entrenched social insurance offices will supplemented the development of the market in this region throughout the years.

Technological Innovation in Medical Field to Offer Rich Market Opportunity

As the applications and strategies related with it have extended, Interventional Radiology has developed as a medicinal claim to fame. The most well-known interventional radiology methods include: angiography, swell angioplasty, biliary waste and stenting, focal venous access, embolization, chemo-embolization, and uterine corridor embolization. Extra strategies including interventional radiology are: needle biopsies, gastronomy tubes, hemodialysis access and support, thrombolysis, and transjugular intrahepatic portosystem shunt (TIPS). Catheter-based indicative and restorative apparatuses, for instance, fast trade catheters and transcatheter applications have been as of late presented alongside ceratoid supply route stenting, as new ways to deal with flow medications of fringe vascular infections utilizing more up to date stent advances.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1337

Besides, the advancement of new strategies in market, for instance, Optical Coherence Tomography (OCT) and Fractional Flow Reserve (FFR) are driving the market of Interventional Radiology. Though, the constrained or no repayment offices for the interventional radiology is restricting the improvement of market.
Posted by at No comments:
Labels:

Wednesday, 21 March 2018

Hip Replacement Implant Market to Become Worth US$9.1 bn by 2024

According to a new study by Transparency Market Research (TMR), the global hip replacement implant market demonstrates a highly competitive and fragmented structure, thanks to the presence of a number of established vendors of hip replacement implants across the world. The leading participants in this market are B. Braun Melsungen AG, DJO Global, Inc., Zimmer Biomet Holdings, Inc., Exactech, Inc., Johnson & Johnson, OMNIlife science, Inc., MicroPort Scientific Corporation, Smith & Nephew, and Stryker Corporation. For the sustenance in this competitive environment, these players are focusing on technological advancements and expanding their regional boundaries. Innovation and price differentiations are also being kept in focus by these participants to gain an edge over their rivals, states the research report.

Read Report Overview: https://www.transparencymarketresearch.com/hip-replacement-implants-market.html

Global Hip Replacement Implant Market to Report 3.90% CAGR between 2016 and 2024

As per the study, the worldwide market for hip replacement implant, which stood at US$6.5 bn in 2015, is anticipated to proliferate at a CAGR of 3.90% during the period from 2016 to 2024. The valuation of this market is likely to touch US$9.1 bn by the end of the period of the forecast. Currently, the total hip replacement implants segment is enjoying the most prominent position in this market and analysts expect that this trend is likely to continue over the next few years. Hospitals have surfaced as the leading end user of hip replacement implants across the world. The scenario is projected to remain like this over the forthcoming years.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1901

In terms of the region, North America emerged as the leading regional market for hip replacement implant in 2015. With a revenue share of 52.7% in the global market, this regional market is anticipated to remain on the top by the end of the forecast period, reports the market study.

Increasing Number of Elderly People to Boost Market

“The global market for hip replacement implants gains significantly from the increasing base of geriatric population across the world, as elderly people is the more prone to weakening of bones, resulting into joint-related problems, says the author of this study. The rising incidence of accidents and the increasing prevalence of osteoarthritis are also propelling this market tremendously.

 Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1901

Going forward, the market is likely to benefit from the technological advancements in hip replacement implants substantially. The increasing investments for research and development activities in this field are also projected to boost this market in the near future. On the flip side, the expensiveness hip replacement implants is expected to hold back this market over the next few years. The high cost incurred in the treatment and post-surgical maintenance is also projected to slow down the growth of this market to some extent, states the research report.
Posted by at No comments:
Labels:

Medical Image Analysis Software Market Opportunity will Rise to US$4.66 bn by 2024

According to Transparency Market Research, the market is foreseen to experience significant growth with a strong CAGR of 8.10% within the forecast period, to attain a value of US$4.66 bn by 2024. Geographically, North America leads the race and in 2015 held 34% of overall market shares.

Rising Trend of Using of EHR to Propel Demand of Medical Image Analysis Software

Owing to rise in number of chronic illness around the world, the demand for medical image analysis software is a rising. Furthermore, the trend of utilizing electronic health records to store, circulate and manage patient’s health information as medical images is also boosting the medical image analysis software market. Besides, as a result of constant medical innovations, for example, computer aided diagnosis, there is a scope for tremendous progress in the usage of new and improved medical image software devices supporting in the treatment of a various types of sicknesses like tumor.

Read Report Overview: https://www.transparencymarketresearch.com/medical-image-analysis-software-market.html

In the medical image analysis, the health related issues are examined with the help of computerized image and different other imaging modalities. Medical image analysis software is used to improve the adequacy and proficiency of medical treatment. The upsides of utilizing such kind of software are upgraded image quality, high determination of images and multi-modular imaging stages which are favored by doctors. It also enables sharing of medical image records among specialists and healing centers thereby making the task of diagnosing and treating much easier. These are the components driving the worldwide medical image analysis software market.

Increase in Investments by Public and Private Firm to Fuel Overall Market Growth

The development of the market is credited to progress in medical imaging frameworks and analysis software, private and public investments in the medical imaging market, expanding utilization of imaging devices because of increase in the cases of chronic ailments, and rising uses of computer aided diagnosis. Developing requirement for automated image analysis devices, rising acceptance of cloud-based imaging systems, and undiscovered developing markets are expected to offer critical development scope for manufacturers in the coming few years.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5306

With the emergence of various leading players the overall medical image analysis software market exhibits an exceptionally fragmented landscape. Some of the prominent participants in the market are Siemens Healthineers, GE Healthcare, Hologic Inc., Pie Medical Imaging, Agfa-Gevaert N.V., Carestream Health, Inc., AQUILAB, Esaote SpA, Philips Healthcare, Sciencesoft USA Corporation, Mirada Medical Limited, Analogic Corporation, Merge Healthcare Inc., and Toshiba Medical Systems Corporation. These players, all things considered, are foreseen to account for 23.5% of the entire market in year in 2015. The report likewise profiles organizations that are predicted to stay dynamic in the worldwide medical image analysis software market till 2022. As of now, organizations are effectively engaged with product development to gain a competitive edge over their companions. Nevertheless, an attempt towards mergers and collaborations can be seen over the coming years.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5306
Posted by at No comments:
Labels:

Prostate Cancer Therapeutics Market Opportunity will Rise to US$ 17.53 bn by 2024

According to estimates presented by TMR, the global prostate cancer therapeutics market is likely to clock a CAGR of 8.19% between 2017 and 2024 vis-à-vis revenue. At this rate, the opportunities in the market are expected to be worth US$17,535.3 mn by the end of 2024 from US$10,107.6 mn in 2017. By therapy type, hormone therapy is currently most attractive and is predicted to stay this way over the forecast period. Hospital pharmacy is the leading distribution channel segment as it stocks various medicines needed at different stage of treatment.

Read Report Overview: https://www.transparencymarketresearch.com/prostate-cancer-therapeutics-market.html

Launch of New Treatment Options Stimulates Growth

Majorly fuelling the global prostate cancer therapeutics market is rising incidence of prostate cancer. As per data published by Cancer Research - a U.K. based government institute, 11,287 prostate cancer deaths were reported in the country in 2014. Prostate cancer is a serious health condition among men that impacts quality of life to a high degree. Although the real cause of prostate cancer remains unknown, obesity and past history of cancer are some key factors associated with the condition. Regular screening, early diagnosis, and advances in medical science have enabled increased survival rate of prostate cancer.
Advances in medical science leading to launch of promising treatment options is fuelling the prostate cancer therapeutics market. Various diagnostic techniques have enabled detection of prostate cancer at an early stage. Measurement of prostate-specific antigen (PSA) has enabled early detection of prostate cancer. Some other promising therapies in phase II and phase III clinical trials for prostate cancer detection include hormonal agents, cytotoxic agents, and other antiprostate-specific membrane antigen therapies.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6562

Furthermore, as per the Mayo Foundation for Medical Education and Research, a combination of anti-cytotoxic T-lymphocyte-associated antigen and hormonal therapies can stir targeted immune response against prostate tumors.

Development of new drugs and novel therapeutic biological products are aiding the prostate cancer therapeutics market. Prominent players are aggressively engaged in R&D for developing novel therapeutics to enhance survival rate of prostate cancer patients. At present, several molecular agents are in early phase clinical trials for the treatment of prostate cancer. In addition, high adoption of hormone-refractory prostate cancer drug due to fewer side effects is providing new prospects to prostate cancer therapeutics market.
Apart from this, in developed countries, increased life expectancy has led to the rise in geriatric population that are at higher risk of developing prostate cancer. Hence, growing geriatric population along with sedentary lifestyle are some prime factors behind increasing prevalence of prostate cancer.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6562

High Cost of Targeted Therapies Make them Unaffordable

On the other hand, high cost of treatment of prostate cancer is holding back the growth of the prostate cancer therapeutics market. High costs of targeted therapies and other immunotherapies is unaffordable by a large population especially in developing and underdeveloped economies. In addition, reluctance toward adoption of premium treatments is another factor challenging the market’s growth. Most oncologists do not opt for systemic therapies for early state prostate cancer due to negative perception toward systemic therapy.

The global prostate cancer therapeutics market is highly consolidated with a handful of large players, namely Pfizer Inc., Janssen Biotech Inc., and Amgen that hold majority market share, says Transparency Market Research (TMR) in a new market study. These companies are engaged in research and development, manufacture, and commercial availability of new drugs. Acquisitions and strategic alliances are some other growth strategies adopted by key players in the prostate cancer therapeutics market. For example, in 2016, Pfizer Inc. announced the successful completion of acquisition of Medivation Inc., the latter’s portfolio includes Xtandi – a leading hormone therapy in the U.S. 
Posted by at No comments:
Labels:

Friday, 2 March 2018

Physiotherapy Devices Market to Become Worth US$2,838.9 mn by 2025

Transparency Market Research produced a report that estimates the progress of the market along key parameters. It is prognosticated that the market value would elevate to US$2,838.9 mn by the end of 2025 as compared to a value of US$1,686.1 mn in 2016. These robust growth figures are expected to reap a CAGR of 6.1% over the period from 2017 to 2025. Based on the type of products available in the market, the electrotherapy equipment is likely to dominate the segment due to its expansive usage. Along regional lines, North America is expected attain supremacy over all other players during the forecast period.

Read Report Overview: https://www.transparencymarketresearch.com/physiotherapy-devices-market.html

Increase in Strenuous Activities and Ailments of Geriatric Populace to Bolster Market

Physiotherapies are an effective option to treat a medley of disabilities and neurological disorder, which is the prime reason behind the popularity of physiotherapy devices. The instance of musculoskeletal diseases has risen in recent years that has created room for these devices across various public healthcare units and private hospitals. The entire world is now driven towards engaging in sportive endeavors that has increased the possibility physical injuries, thus, escalating the demand within the market. The prevalence of neurological disorders and muscular amongst the geriatric populace calls for physiotherapies due to their non-intrusive nature. Henceforth, the growing geriatric population is also skyrocketing the demand for these products. Due to the relative effectiveness of these therapies as against surgical treatments, the medical practitioners have also been recommending physiotherapies to patients.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=28517
Advancements in physiotherapy devices has instilled renewed hopes amongst people disables for prolonged periods of time, which is another important standpoint for the growth of the market. A number of healthcare centers have surfaced across the globe that inhabit the patients in their premises and administer long-term physiotherapy plans. This has propelled the growth of the market across the globe and has spiked up opportunities for market players.

Lack of Skilled Therapists Leads to Distrust Amongst Patients

Physiotherapy devices are technologically advanced which means that the therapists require palpable knowledge to operate them. The lack of skilled physiotherapists has placed a negative toll upon the market, especially in the developing economies. Moreover, the apprehensions associated with the lack of knowledge amongst the physiotherapists has given rise to distrust amongst the patients. Another hindrance for the global market is the high cost of these devices that holds back several practitioners to install these devices within their framework. However, in the absence of viable alternatives, the devices are expected to gain popularity and perpetuate market growth.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28517

The global physiotherapy devices market is anticipated to experience a prominent surge in demand over the coming years. Hence, the market players want to optimize the lucrativeness of their operations within the market by resorting to a range of business strategies. The coexistence of huge market players with several local and regional vendors has birthed intense competition within the market. To retain their dominance and gain a greater market share, the well-established players are aiming to differentiate their products from the products developed by competitors. Moreover, the market would excavate positive results for market player who succeed in dispelling innovative products at affordable prices. Mergers and acquisitions are expected to define the crux of the market as a large number of international players incline towards these strategies. The contemporary players in the market include Dynatronics Corporation, EMS Physio Ltd., BTL, DJO Global, Patterson Medical Ltd.,and Enraf-Nonius.
Posted by at No comments:
Labels:

Tumor Ablation Market to Become Worth US$1.9 bn by 2024

A recent study by Transparency Market Research (TMR) has detected that the competition in the global tumor ablation market is intense, in a fragmented scenario with the presence of a number of participants. That being said, there are plenty of growth opportunities too in the market for tumor ablation, which will continue to attract pharmaceutical companies and further intensify the competition. The TMR report projects the global tumor ablation market to witness a healthy growth rate of 12.20% during the forecast period of 2016 to 2024, reaching an estimated valuation of US$1.9 bn by 2024, considerably up from its evaluated worth of US$702.9 mn in 2015.

Read Report Overview: https://www.transparencymarketresearch.com/tumor-ablation-market.html

Among the key vendors currently operating in the global tumor ablation market, is Medtronic plc. The company has a diverse product portfolio and continues to add new products as well as enhances the successful ones. Geographical expansion has also helped Medtronic to gain ground over its competitors. In the near future, some of the other prominent companies, such as Ethicon, Boston Scientific, and AngioDynamics, are expected to depend on product innovation to stay afloat in the fragmented and competitive landscape.

Radiofrequency Ablation Profitable Technology Segment

Technology-wise, this report segments the global tumor ablation market into microwave ablation, laser interstitial thermal ablation, high-intensity focused ultrasound, and radiofrequency ablation, which currently is the most profitable segment. The demand for radiofrequency segment is projected for a CAGR of 10.90% during the forecast period of 2016 to 2024, significantly exceeding the overall growth rate of the market for tumor ablation. This substantial demand for tumor ablation is a reflection of several benefits offered by the procedure, which is efficient, causes nominal damage to the tissues, and offers high-density focused ultrasound.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=18656

Based on material, the report segments the global tumor ablation market into cancers of liver, lung, kidney, bone, breast, and prostate. Liver cancer is more common among men than women, and has significant demand, although lung cancer category is high profitable too, primarily as a result of changing lifestyle among the urban population.

North America Remains Highly Profitable

Out of five regions analyzed by the report: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, the former accounted for nearly a third (30%) of the global demand in the tumor ablation market. In the near future, North America will continue to be the most lucrative region, gaining traction from factors such as high adoption rate of new technology, robust healthcare infrastructure, escalating geriatric population percentage, and high prevalence of cancer. Europe is another profitable region, although vastly populated Asia Pacific will turn into a highly profitable region as the technology goes cheaper and reaches widespread unmet demands.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18656

Prevalence of Cancer Driving Demand

A number of factors are ensuring the prosperity of the global tumor ablation market in the near future, such as growing geriatric population across the world, technological advancements in ablation devices, increasing population base of cancer patients, which is a chronic disease, mushrooming number of hospitals, ablation centers, and surgical facilities across the globe, changing lifestyle, and government benefits for the companies indulging the in the research and development in this field. On the other hand, while cost constraints continue to hinder the proper progress of the market for tumor ablation, ongoing healthcare reforms is not supporting the current inflow of the demand.
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)